Semaglutide

The GLP-1 Receptor Agonist

Comprehensive evidence-based information on weight management and blood sugar control

Primary Benefit

Weight Management & Blood Sugar

Administration

Injectable

Status

FDA-Approved Drug

Clinical Insights

Evidence-based analysis from Dr. Jobby John, PharmD, FACA

Provider Access

What is Semaglutide?

Semaglutide is a peptide that has gained widespread recognition for its profound effects on blood sugar control and weight management. It is the active ingredient in well-known FDA-approved medications like Ozempic®, Wegovy®, and Rybelsus®.

A Natural Mimic

Semaglutide is designed to mimic a natural hormone in your body called GLP-1 (glucagon-like peptide-1).

The Control Signal

By acting like GLP-1, it sends powerful signals to the brain, pancreas, and stomach to help regulate appetite and blood sugar.

Research and Potential Benefits

Semaglutide's most prominent benefit is significant weight loss, as demonstrated in the landmark STEP clinical trials.

  • Reduces Appetite: It acts on brain centers to reduce hunger and increase feelings of fullness.
  • Slows Digestion: It slows how quickly the stomach empties, helping you feel full for longer.
  • Clinically Proven: Studies have shown average weight loss of 15-20% of body weight in individuals with obesity.

Originally developed for type 2 diabetes, Semaglutide is highly effective at managing blood glucose levels.

  • Stimulates Insulin: It prompts the pancreas to release insulin when blood sugar is high.
  • Suppresses Glucagon: It reduces the release of glucagon, a hormone that raises blood sugar.

As an FDA-approved medication, Semaglutide has a well-documented safety profile but must be used under medical supervision.

  • ! Prescription Required: It is not a supplement and requires a prescription from a licensed healthcare provider.
  • ! Common Side Effects: Gastrointestinal issues like nausea, vomiting, and diarrhea are common, especially when starting.
  • ! Contraindications: Not suitable for people with a personal or family history of medullary thyroid carcinoma or MEN 2.

References & Citations

  1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. Source.
  2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Source.
Dr. Jobby John

Ask Dr. John About Semaglutide

Get personalized clinical insights from Dr. Jobby John, PharmD, FACA. Ask specific questions about Semaglutide and receive evidence-based answers from his extensive clinical experience.

Ask about dosing, side effects, patient selection, monitoring, contraindications, or clinical experience

HIPAA-compliant responses

Common Questions About Semaglutide